Financiado en parte por Blackmores Australia Ltd.
Effect of Fish Oil Supplementation on Hepatic and Visceral Fat in Overweight Men: A Randomized Controlled Trial
Parker HM, Cohn JS, O'Connor HT, Garg ML, Caterson ID, George J, Johnson NA
Nutrients · 34 citas
Etiquetas de revisión
Financiado por la industriaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiado por la industria
- Empresa
- Blackmores Australia Ltd.
Según 1 financiador declarado.
Publicación
- Publicado
- 2019-02-23 · Nutrients · vol. 11 · número 2 · pág. 475
- Editorial
- Multidisciplinary Digital Publishing Institute
- Citado
- 52 citas · más que el 96% de estudios similares · 5.1× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 63 trabajos
- Acceso
- Acceso abierto (revista) · CC-BY
- Áreas de investigación
- Liver Disease Diagnosis and Treatment · Fatty Acid Research and Health · Diet, Metabolism, and Disease
- Palabras clave
- Fish oil, Medicine, Fatty liver, Internal medicine, Overweight, Placebo, Randomized controlled trial, Polyunsaturated fatty acid, Endocrinology, Adipose tissue, Nonalcoholic fatty liver disease, Gastroenterology, Obesity, Physiology, Biology, Fatty acid, Pathology, Disease, Biochemistry
- MeSH
- liver, humans, fatty acids, omega-3, fish oils, body composition, dietary supplements, adult, male, intra-abdominal fat, overweight, non-alcoholic fatty liver disease
7 autores
- Helen M. Parker🇦🇺 · autor de correspondenciaThe University of Sydney
- Jeffrey S. Cohn🇦🇺The Heart Research Institute
- Helen T O'Connor🇦🇺The University of Sydney
- Manohar L. Garg🇦🇺University of Newcastle Australia
- Ian Douglas Caterson🇦🇺The University of Sydney
- Jacob George🇦🇺The University of Sydney; Westmead Institute; Westmead Institute for Medical Research
- Nathan Anthony Johnson🇦🇺The University of Sydney
Resumen
El texto original del estudio, en el idioma en que se publicó.
Being overweight increases the risk of the development of metabolic conditions such as non-alcoholic fatty liver disease (NAFLD), which is itself an independent predictor of cardiovascular disease. Omega-3 polyunsaturated fatty acid (PUFA) supplementation is recommended for prevention of chronic disease, and is thought to reduce raised liver fat, yet there have been few randomized controlled trials with accurate measurement of liver fat. We assessed the effect of 12 weeks of supplementation with omega-3 PUFA from fish oil versus placebo on quantified liver fat, liver tests, and body composition including visceral adipose tissue (VAT) in a double-blind randomized controlled trial. Fifty apparently healthy overweight men (BMI 25.0⁻29.9 kg/m²; waist > 94 cm) were randomly allocated to consume fish oil (total daily dose: 1728 mg marine triglycerides, of which 588 mg EPA and 412 mg DHA, combined with 200 mg antioxidant, coenzyme Q10) or placebo (olive oil capsules) daily for 12 weeks. Liver fat was assessed using proton magnetic resonance spectroscopy. All outcomes were assessed at baseline and following 6 and 12 weeks of supplementation. Baseline liver fat was 4.6 ± 0.5% (range: 0.6 to 18.2%); 16 (32%) participants met the criteria for NAFLD (>5.5% liver fat). Repeated measures ANOVA revealed no significant time or group × time effect for fish oil versus placebo for liver fat, liver enzymes, anthropometry, or body composition including VAT (p > 0.05 for all), with similar finding for sub-analysis of participants with NAFLD. Omega-3 PUFA did not appear to be an effective agent for reducing liver fat in overweight men. The factors determining the health benefits of omega-3 PUFA supplementation on an individual level need to be clarified.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.